Asep Inc. has developed a proprietary peptide technology that directly addresses the ineffectiveness of current treatment options by suppressing biofilm regrowth and reducing inflammation.
Potent activity against all major clinically relevant bacteria growing as antibiotic-resistant biofilms.
Work in combination with conventional antibiotics to overcome antibiotic resistance.
Safe and Effective in Animal Infection Models
Work in in vivo models of biofilm infections such as sinusitis and abscesses.
Anti-inflammatory Activity in vivo
As strong as the nonsteroidal anti-inflammatory drug indomethacin.
Immune modulating activity
Suppress harmful inflammation while boosting protective innate immunity.
Optimized peptides with combined activity profiles for clinical applications.
The company is pursuing clinical validation in the treatment of organisms associated with Sinusitis pathogens in a planned study in Vancouver, Canada, along with other development efforts:
In vitro and in vivo anti inflammatory and immunomodulatory activities have been extensively characterized.
Peptides have demonstrated excellent activity profiles in relevant biofilm infection models of sinusitis and infected wounds.
New formulations, initial pharmacokinetics and pharmacodynamics studies have been defined and/or developed.